Episode 181 - May 1, 2026

What It Covers

Biotech Hangout Episode 181 covers May 2026 biotech market performance, with the XBI up 8% year-to-date outperforming the S&P 500 by 300 basis points. Hosts analyze 10 IPOs totaling $3.2 billion, major M&A activity led by Eli Lilly's six acquisitions, Revolution Medicines' pancreatic cancer phase three data, and Harmony Three's failed interim PFS analysis.

Key Questions Answered

• •Biotech IPO Market Quality: Ten biotech IPOs have raised $3.2 billion year-to-date through May 2026, with standout deals including Cholera Therapeutics at $719 million, Avillin Pharmaceuticals at $300 million trading up 60% on debut, and DeepCorp Therapeutics raising $255 million. The current cohort reflects companies with extended private incubation periods and existing clinical data, distinguishing this window from prior frothy cycles where earlier-stage companies dominated.
• •Eli Lilly M&A Cadence: Lilly has executed six acquisitions totaling approximately $14.5 billion upfront in 2026 alone, averaging roughly one deal every two weeks. Targets span early-stage assets in myeloma, myelofibrosis, sleep disorders, and JAK inhibition. Investors tracking pharma M&A should monitor Lilly separately, as its GLP-1 cash generation creates acquisition capacity that distorts sector-wide deal volume metrics and obscures the activity levels of other buyers.
• •Revolution Medicines Pancreatic Data: Daraxon RASib, a pan-RAS inhibitor, delivered a 60% reduction in death risk versus chemotherapy in second-line pancreatic cancer, with median overall survival of 13.2 months compared to 6.7 months for chemo. First-line monotherapy data showed a 47% overall response rate and 83% six-month overall survival. The data enabled a $2.2 billion equity and debt raise, upsized from an original $1 billion target.
• •Generalist Investor Behavior Pattern: Generalist long-only funds enter biotech positions without sustained engagement — analysts conduct limited meetings, then large portfolio managers appear once, ask few questions, and subsequently hold $300–400 million positions revealed only in quarterly 13F filings. Biotech specialists should track 13F filings actively rather than relying on investor relations meeting frequency as a proxy for institutional interest, since generalist conviction builds invisibly before deployment.
• •Type Two JAK Inhibitor Differentiation: Lilly's $3.2 billion acquisition of Ajax Therapeutics targets a type two JAK inhibitor in phase one for myeloproliferative neoplasms including myelofibrosis and polycythemia vera. Unlike approved type one JAK inhibitors carrying black box warnings for elevated all-cause mortality, type two binding conformation offers potential safety and efficacy improvements. Investors should monitor whether type two JAK inhibitors expand into autoimmune and inflammatory indications beyond rare blood cancers.
• •IPO Cycle Risk Management: Biotech IPO windows historically close via two mechanisms: the pipeline of high-quality companies exhausts itself and weaker companies begin breaking deals, or broader biotech market weakness eliminates buyer demand regardless of company quality. Venture investors and issuers should prioritize aftermarket performance monitoring over deal pricing as the leading indicator of window sustainability, since deteriorating post-IPO trading precedes formal market closure by weeks.